Skip to main content
SpringerLink
Log in

Glucagon I

  • Book
  • © 1983

Overview

Editors:
  1. Pierre J. Lefèbvre

    1. University of Liège, Belgium
      University of Brussels (V.U.B.), Belgium
      Royal Academy of Medicine of Belgium, Belgium
      Medical Policlinics, University of Liège, Belgium
      Division of Diabetes, University of Liège, Belgium
      Institut de Mèdecine, Hôpital de Bavière, Liège, Belgium

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 66 / 1)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (22 chapters)

  1. Front Matter

    Pages I-XXVIII
    Download chapter PDF

  2. Chemistry and Physicochemistry of Glucagon

    1. Front Matter

      Pages ins1-ins1
      Download chapter PDF

    2. Chemical Characteristics of Glucagon

      • W. W. Bromer
      Pages 1-22

    3. The Chemical Synthesis of Glucagon

      • R. B. Merrifield, S. Mojsov
      Pages 23-35

    4. The Conformation of Glucagon

      • T. L. Blundell
      Pages 37-56

  3. Morphology of the A-cell of Islets of Langerhans, Biosynthesis of Glucagon and Related Peptides

    1. Front Matter

      Pages ins2-ins2
      Download chapter PDF

    2. Glucagon- and Glicentin-Producing Cells

      • L. Orci, C. Bordi, R. H. Unger, A. Perrelet
      Pages 57-79

    3. Ontogeny and Phylogeny of the Glucagon Cell

      • S. Falkmer, S. Van Noorden
      Pages 81-119

    4. The Biosynthesis of Glucagon

      • C. Hellerström
      Pages 121-138

    5. Glucagon, Glicentin, and Related Peptides

      • A. J. Moody, L. Thim
      Pages 139-174

  4. Production and Assay of Glucagon

    1. Front Matter

      Pages ins3-ins3
      Download chapter PDF

    2. Glucagon Preparations

      • M. Pingel, B. Skelbaek-Pedersen, J. Brange
      Pages 175-188

    3. The Immunogenicity of Glucagon

      • L. G. Heding
      Pages 189-201

    4. Immunoassays for Glucagon

      • J. W. Ensinck
      Pages 203-221

    5. Heterogeneity of Circulating Glucagon and Glucagon-Like Immunoreactivity

      • I. Valverde
      Pages 223-244

    6. Radioreceptorassays for Glucagon

      • J. J. Holst
      Pages 245-261

  5. Actions of Glucagon

    1. Front Matter

      Pages ins4-ins4
      Download chapter PDF

    2. The Actions of Glucagon at Its Receptor: Regulation of Adenylate Cyclase

      • M. Rodbell
      Pages 263-290

    3. Glucagon and Liver Glycogen Metabolism

      • W. Stalmans
      Pages 291-314

    4. Glucagon and Gluconeogenesis

      • T. H. Claus, C. R. Park, S. J. Pilkis
      Pages 315-360
Back to top

Keywords

About this book

The Editorial Board of the Handbook of Experimental Pharmacology apparently did not hurry in suggesting production of a volume on glucagon since the present opus is number sixty-six in the series. This fact is even more striking if we consider that 34 volumes published over about eight years will separate the books on glucagon from those on insulin on library shelves, whereas only a few microns separate the cells manufacturing these two polypeptides within the islets of Langerhans in the pancreas! Numerous factors have probably caused this dicrimination; four of them are: First, insulin deficiency or resistance is the cause of one of the most serious and distressing diseases, diabetes mellitus, which affects millions of people, whereas glucagon deficiency is apparently an extremely rare disorder, for which detailed reports are published of individual cases whenever they occur. Second, since its discovery in 1921 by BANTING and BEST, insulin has been irreplaceable for the treatment of the most severe forms of diabetes, whereas, in contrast, glucagon was until recently considered a relatively minor therapeutic agent. Third, whereas insulin is a compound which has been well characterized since the pioneering work of SANGER and its biosynthesis clearly identified by STEINER and his co-workers, glucagon, also well characterized chemically, has suffered from its parenthood with the so-called "glucagon-like immunoreactive substances", an incompletely defined series of immunologically related polypeptides present in the gut, the pancreas and some other parts of the body.

Editors and Affiliations

  • University of Liège, Belgium

    Pierre J. Lefèbvre

  • University of Brussels (V.U.B.), Belgium

    Pierre J. Lefèbvre

  • Royal Academy of Medicine of Belgium, Belgium

    Pierre J. Lefèbvre

  • Medical Policlinics, University of Liège, Belgium

    Pierre J. Lefèbvre

  • Division of Diabetes, University of Liège, Belgium

    Pierre J. Lefèbvre

  • Institut de Mèdecine, Hôpital de Bavière, Liège, Belgium

    Pierre J. Lefèbvre

Bibliographic Information

  • Book Title: Glucagon I

  • Editors: Pierre J. Lefèbvre

  • Series Title: Handbook of Experimental Pharmacology

  • DOI: https://doi.org/10.1007/978-3-642-68866-9

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1983

  • Softcover ISBN: 978-3-642-68868-3Published: 19 November 2011

  • eBook ISBN: 978-3-642-68866-9Published: 06 December 2012

  • Series ISSN: 0171-2004

  • Series E-ISSN: 1865-0325

  • Edition Number: 1

  • Number of Pages: XXX, 536

  • Topics: Pharmacology/Toxicology, Pharmacy

Publish with us

Policies and ethics

Back to top

Search

Navigation